samedan logo

 
 
spacer
home > ebr > winter 2003 > technical and commercial due diligence in biotech transactions: doing the right things and doing them right
PUBLICATIONS
European Biopharmaceutical Review

Technical and Commercial Due Diligence in Biotech Transactions: Doing the Right Things and Doing them Right

This article argues that conducting due diligence properly to ensure that potential risks and opportunities in biotechnology transactions are fully understood is more important than ever as M&A and technology licensing activities accelerate. There are many ways to go about conducting due diligence, and the factors that determine the right way to proceed are discussed, with the pros and cons set out for taking an in-house approach, versus hiring external consultants. Whatever approach is taken, a due diligence plan is vital, given the often short timescales in which deals need to be closed. Keys to success are ensuring that an independent view is taken and that the right questions are asked, such that the answers truly help to support the investment decision. Due diligence can be an intensive and time-consuming process so the task should not be underestimated or left to the last minute - while it has costs in terms of time or professional fees, cutting corners can turn out to be far more costly.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Simon Shohet, Head of Healthcare and Life Sciences Consulting Team at Cambridge Consultants Ltd

Simon Shohet has been a strategic and commercial advisor and analyst for organisations in the biotechnology and health care industry for over 12 years. Presently, he leads the Healthcare and Life Sciences Consulting team at Cambridge Consultants Ltd (CCL), a sister company of the international management consulting firm Arthur D Little. His team works for European, US and Asia-Pacific-based corporations as well as start-ups and government agencies, helping them to gain competitive advantage through strategic exploitation of life science and biomedical technologies. Before entering consulting he held posts at the Confederation of British Industry (CBI) as a Biotechnology Policy Adviser and London Business School as a Research Fellow in technology economics. He holds a PhD in Microbiology from University College London, and a BSc from the University of Edinburgh. Simon has published numerous papers and articles in management and scientific literature.

spacer
Simon Shohet
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo received the Customer Satisfaction Management Certificate (ISO 10002).

Turkish Cargo, the fastest growing air cargo brand in the world, obtained the "Customer Satisfaction Management Certificate" (ISO 10002) and developed the Cargo Customers Feedback Management Policy accordingly.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement